Janus Henderson Group PLC Trims Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Janus Henderson Group PLC lowered its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 46.4% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,395,058 shares of the biopharmaceutical company's stock after selling 2,940,177 shares during the period. Janus Henderson Group PLC owned about 1.14% of Amicus Therapeutics worth $31,980,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of FOLD. Park Avenue Securities LLC purchased a new position in Amicus Therapeutics in the fourth quarter valued at about $123,000. Avanza Fonder AB purchased a new position in Amicus Therapeutics in the fourth quarter valued at about $157,000. KBC Group NV boosted its holdings in Amicus Therapeutics by 44.4% in the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock valued at $96,000 after purchasing an additional 3,120 shares during the last quarter. R Squared Ltd acquired a new stake in Amicus Therapeutics during the fourth quarter valued at approximately $79,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in Amicus Therapeutics by 11.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 63,358 shares of the biopharmaceutical company's stock valued at $597,000 after buying an additional 6,314 shares in the last quarter.

Amicus Therapeutics Stock Down 2.3%

Shares of Amicus Therapeutics stock opened at $5.88 on Thursday. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. The business's 50 day simple moving average is $7.47 and its 200-day simple moving average is $8.99. The stock has a market capitalization of $1.81 billion, a price-to-earnings ratio of -32.67, a PEG ratio of 1.51 and a beta of 0.64. Amicus Therapeutics, Inc. has a twelve month low of $5.82 and a twelve month high of $12.65.

Wall Street Analysts Forecast Growth

FOLD has been the topic of several research reports. UBS Group upped their price objective on Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. StockNews.com cut Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Cantor Fitzgerald restated an "overweight" rating and set a $21.00 price objective on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Finally, The Goldman Sachs Group cut their price objective on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research note on Friday, May 2nd. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Amicus Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $16.22.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.